Background: The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in a neonatal screening test for congenital adrenal hyperplasia in a preterm girl exposed to zidovudine, efavirenz, tenofovir, and emtricitabine. Objective: So far, HIV drugs have not been tested for their effect on steroidogenesis and the steroidogenic enzyme activity of CYP21A2 specifically in an in vitro system. Methods: We tested the effect of efavirenz, tenofovir, emtricitabine, and zidovudine on steroidogenesis of human adrenal H295R cells. Cells were treated with the drugs at different concentrations including concentrations in therapeutic use. The effect on CYP21A2 activity was assessed by testing the conversion of radiolabeled 17OHP to 11-deoxycortisol. Cell viability was tested by an MTT assay. In addition, recombinant human CYP21A2 protein was used to assess direct drug effects on CYP21A2 activity. Results: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations. Moreover, efavirenz affected cell viability. By contrast, the other test drugs did not affect steroidogenesis. Follow-up of our patient revealed elevated 17OHP and androgen levels during the first weeks of life, but values normalized spontaneously. Genetic testing for CYP21A2 mutations was negative. Thus, it remains unsettled whether the transient 17OHP elevation in this baby was due to a drug effect. Conclusion: The HIV drug efavirenz inhibits CYP21A2 activity in vitro through direct interaction with enzyme catalysis at therapeutic concentrations. This may have clinical implications for HIV treatment in children and adults. However, so far, clinical data are scarce, and further studies are needed to be able to draw clinical conclusions.

1.
Speiser
PW
,
Azziz
R
,
Baskin
LS
,
Ghizzoni
L
,
Hensle
TW
,
Merke
DP
, et al.;
Endocrine Society
.
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline
.
J Clin Endocrinol Metab
.
2010
Sep
;
95
(
9
):
4133
60
.
[PubMed]
0021-972X
2.
Miller
WL
,
Auchus
RJ
.
The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders
.
Endocr Rev
.
2011
Feb
;
32
(
1
):
81
151
.
[PubMed]
0163-769X
3.
Speiser
PW
,
Arlt
W
,
Auchus
RJ
,
Baskin
LS
,
Conway
GS
,
Merke
DP
, et al.
Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline
.
J Clin Endocrinol Metab
.
2018
Nov
;
103
(
11
):
4043
88
.
[PubMed]
0021-972X
4.
White
PC
,
Speiser
PW
.
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
.
Endocr Rev
.
2000
Jun
;
21
(
3
):
245
91
.
[PubMed]
0163-769X
5.
Goto
M
,
Piper Hanley
K
,
Marcos
J
,
Wood
PJ
,
Wright
S
,
Postle
AD
, et al.
In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development
.
J Clin Invest
.
2006
Apr
;
116
(
4
):
953
60
.
[PubMed]
0021-9738
6.
White
PC
.
Neonatal screening for congenital adrenal hyperplasia
.
Nat Rev Endocrinol
.
2009
Sep
;
5
(
9
):
490
8
.
[PubMed]
1759-5029
7.
van der Kamp
HJ
,
Oudshoorn
CG
,
Elvers
BH
,
van Baarle
M
,
Otten
BJ
,
Wit
JM
, et al.
Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight
.
J Clin Endocrinol Metab
.
2005
Jul
;
90
(
7
):
3904
7
.
[PubMed]
0021-972X
8.
Ng
PC
,
Wong
GW
,
Lam
CW
,
Lee
CH
,
Wong
MY
,
Fok
TF
, et al.
Pituitary-adrenal response in preterm very low birth weight infants after treatment with antenatal corticosteroids
.
J Clin Endocrinol Metab
.
1997
Nov
;
82
(
11
):
3548
52
.
[PubMed]
0021-972X
9.
Flück
CE
.
MECHANISMS IN ENDOCRINOLOGY: Update on pathogenesis of primary adrenal insufficiency: beyond steroid enzyme deficiency and autoimmune adrenal destruction
.
Eur J Endocrinol
.
2017
Sep
;
177
(
3
):
R99
111
.
[PubMed]
0804-4643
10.
Miller
WL
,
Fluck
CE
. Adrenal cortex and its disorders. In: Sperling MA, ed. Pediatric Endocrinology. 4th Ed ed. Pittsburgh: Elsevier;
2014
.
11.
Fleseriu
M
,
Castinetti
F
.
Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies
.
Pituitary
.
2016
Dec
;
19
(
6
):
643
53
.
[PubMed]
1386-341X
12.
Malikova
J
,
Brixius-Anderko
S
,
Udhane
SS
,
Parween
S
,
Dick
B
,
Bernhardt
R
, et al.
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2
.
J Steroid Biochem Mol Biol
.
2017
Nov
;
174
:
192
200
.
[PubMed]
0960-0760
13.
Simon
A
,
Warszawski
J
,
Kariyawasam
D
,
Le Chenadec
J
,
Benhammou
V
,
Czernichow
P
, et al.;
ANRS French Perinatal Cohort Study Group
.
Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers
.
JAMA
.
2011
Jul
;
306
(
1
):
70
8
.
[PubMed]
0098-7484
14.
Kariyawasam
D
,
Simon
A
,
Laborde
K
,
Parat
S
,
Souchon
PF
,
Frange
P
, et al.
Adrenal enzyme impairment in neonates and adolescents treated with ritonavir and protease inhibitors for HIV exposure or infection
.
Horm Res Paediatr
.
2014
;
81
(
4
):
226
31
.
[PubMed]
1663-2818
16.
Dhayat
NA
,
Frey
AC
,
Frey
BM
,
d’Uscio
CH
,
Vogt
B
,
Rousson
V
, et al.
Estimation of reference curves for the urinary steroid metabolome in the first year of life in healthy children: tracing the complexity of human postnatal steroidogenesis
.
J Steroid Biochem Mol Biol
.
2015
Nov
;
154
:
226
36
.
[PubMed]
0960-0760
17.
Dhayat
NA
,
Dick
B
,
Frey
BM
,
d’Uscio
CH
,
Vogt
B
,
Flück
CE
.
Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from the urinary steroid metabolome
.
J Steroid Biochem Mol Biol
.
2017
Jan
;
165
Pt B
:
312
22
.
[PubMed]
0960-0760
18.
Dhayat
NA
,
Frey
AC
,
Frey
BM
,
d’Uscio
CH
,
Vogt
B
,
Rousson
V
, et al.
Corrigendum to “Estimation of reference curves for the urinary steroid metabolome in the first year of life in healthy children: tracing the complexity of human postnatal steroidogenesis” [J. Steroid Biochem. Mol. Biol. 154 (2015) 226-236]
.
[J. Steroid Biochem. Mol. Biol. 154 (2015) 226-236]
.
J Steroid Biochem Mol Biol
.
2018
Oct
;
183
:
238
.
[PubMed]
0960-0760
19.
Bileck
A
,
Verouti
SN
,
Escher
G
,
Vogt
B
,
Groessl
M
.
A comprehensive urinary steroid analysis strategy using two-dimensional gas chromatography - time of flight mass spectrometry
.
Analyst (Lond)
.
2018
Sep
;
143
(
18
):
4484
94
.
[PubMed]
0003-2654
20.
Udhane
SS
,
Legeza
B
,
Marti
N
,
Hertig
D
,
Diserens
G
,
Nuoffer
JM
, et al.
Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems
.
Sci Rep
.
2017
Aug
;
7
(
1
):
8652
.
[PubMed]
2045-2322
21.
Kempná
P
,
Hirsch
A
,
Hofer
G
,
Mullis
PE
,
Flück
CE
.
Impact of differential P450c17 phosphorylation by cAMP stimulation and by starvation conditions on enzyme activities and androgen production in NCI-H295R cells
.
Endocrinology
.
2010
Aug
;
151
(
8
):
3686
96
.
[PubMed]
0013-7227
22.
Brixius-Anderko
S
,
Schiffer
L
,
Hannemann
F
,
Janocha
B
,
Bernhardt
R
.
A CYP21A2 based whole-cell system in Escherichia coli for the biotechnological production of premedrol
.
Microb Cell Fact
.
2015
Sep
;
14
(
1
):
135
.
[PubMed]
1475-2859
23.
Schiffer
L
,
Brixius-Anderko
S
,
Hannemann
F
,
Zapp
J
,
Neunzig
J
,
Thevis
M
, et al.
Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes
.
Drug Metab Dispos
.
2016
Feb
;
44
(
2
):
227
37
.
[PubMed]
0090-9556
24.
Pallan
PS
,
Wang
C
,
Lei
L
,
Yoshimoto
FK
,
Auchus
RJ
,
Waterman
MR
, et al.
Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme-progesterone substrate complex and rate-limiting C-H bond cleavage
.
J Biol Chem
.
2015
May
;
290
(
21
):
13128
43
.
[PubMed]
0021-9258
25.
Krieger
E
,
Darden
T
,
Nabuurs
SB
,
Finkelstein
A
,
Vriend
G
.
Making optimal use of empirical energy functions: force-field parameterization in crystal space
.
Proteins
.
2004
Dec
;
57
(
4
):
678
83
.
[PubMed]
0887-3585
26.
Vriend
G.
WHAT IF: a molecular modeling and drug design program. J Mol Graph
1990
; 8:52-56, 29
27.
Duan
Y
,
Wu
C
,
Chowdhury
S
,
Lee
MC
,
Xiong
G
,
Zhang
W
, et al.
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations
.
J Comput Chem
.
2003
Dec
;
24
(
16
):
1999
2012
.
[PubMed]
0192-8651
28.
Jorgensen
WL
,
Tirado-Rives
J
.
Potential energy functions for atomic-level simulations of water and organic and biomolecular systems
.
Proc Natl Acad Sci USA
.
2005
May
;
102
(
19
):
6665
70
.
[PubMed]
0027-8424
29.
Trott
O
,
Olson
AJ
.
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
.
J Comput Chem
.
2010
Jan
;
31
(
2
):
455
61
.
[PubMed]
1096-987X
30.
Knapp
KM
,
Brogly
SB
,
Muenz
DG
,
Spiegel
HM
,
Conway
DH
,
Scott
GB
, et al.
Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals
.
Pediatr Infect Dis J
.
2012
Feb
;
31
(
2
):
164
70
.
[PubMed]
0891-3668
31.
Brogly
SB
,
Abzug
MJ
,
Watts
DH
,
Cunningham
CK
,
Williams
PL
,
Oleske
J
, et al.
Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C
.
Pediatr Infect Dis J
.
2010
Aug
;
29
(
8
):
721
7
.
[PubMed]
0891-3668
32.
Ford
N
,
Mofenson
L
,
Shubber
Z
,
Calmy
A
,
Andrieux-Meyer
I
,
Vitoria
M
, et al.
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
.
AIDS
.
2014
Mar
;
28
Suppl 2
:
S123
31
.
[PubMed]
0269-9370
33.
Sibiude
J
,
Mandelbrot
L
,
Blanche
S
,
Le Chenadec
J
,
Boullag-Bonnet
N
,
Faye
A
, et al.
Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)
.
PLoS Med
.
2014
Apr
;
11
(
4
):
e1001635
.
[PubMed]
1549-1277
34.
Siberry
GK
,
Jacobson
DL
,
Kalkwarf
HJ
,
Wu
JW
,
DiMeglio
LA
,
Yogev
R
, et al.;
Pediatric HIV/AIDS Cohort Study
.
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy
.
Clin Infect Dis
.
2015
Sep
;
61
(
6
):
996
1003
.
[PubMed]
1058-4838
35.
Mugo
NR
,
Hong
T
,
Celum
C
,
Donnell
D
,
Bukusi
EA
,
John-Stewart
G
, et al.;
Partners PrEP Study Team
.
Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial
.
JAMA
.
2014
Jul
;
312
(
4
):
362
71
.
[PubMed]
0098-7484
37.
Aarnoutse
RE
,
Kleinnijenhuis
J
,
Koopmans
PP
,
Touw
DJ
,
Wieling
J
,
Hekster
YA
, et al.
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
.
Clin Pharmacol Ther
.
2005
Dec
;
78
(
6
):
664
74
.
[PubMed]
0009-9236
38.
Rock
BM
,
Hengel
SM
,
Rock
DA
,
Wienkers
LC
,
Kunze
KL
.
Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4
.
Mol Pharmacol
.
2014
Dec
;
86
(
6
):
665
74
.
[PubMed]
0026-895X
39.
Yeh
RF
,
Gaver
VE
,
Patterson
KB
,
Rezk
NL
,
Baxter-Meheux
F
,
Blake
MJ
, et al.
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
.
J Acquir Immune Defic Syndr
.
2006
May
;
42
(
1
):
52
60
.
[PubMed]
1525-4135
40.
Flück
CE
,
Yaworsky
DC
,
Miller
WL
.
Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2
.
Epilepsia
.
2005
Mar
;
46
(
3
):
444
8
.
[PubMed]
0013-9580
41.
Hamed
SA
.
The effect of epilepsy and antiepileptic drugs on sexual, reproductive and gonadal health of adults with epilepsy
.
Expert Rev Clin Pharmacol
.
2016
Jun
;
9
(
6
):
807
19
.
[PubMed]
1751-2433
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.